This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Clovis Oncology Inc (CLVS)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -160.03M -84.53M -73.98M -55.57M
Operating Gains/Losses 67.00K 0.00 1.16M -16.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 0.00 0.00 0.00 0.00
(Increase) Decrease in Inventories 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables -1.37M 958.00K -758.00K 1.66M
(Decrease) Increase In Other Current Liabilities 3.88M -2.20M -110.00K 1.84M
(Increase) Decrease In Other Working Capital -910.00K 0.00 0.00 924.00K
Other Non-Cash Items 18.22M 10.53M 4.95M 8.32M
Net Cash From Continuing Operations -117.05M -71.71M -65.38M -39.83M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -117.05M -71.71M -65.38M -39.83M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 2.00M 9.61M
Purchases of Property, Plant & Equipment -2.29M -121.00K -1.06M -446.00K
Acquisitions 0.00 -9.91M 0.00 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -2.29M -10.03M 942.00K 9.17M
Issuance of Debt 287.50M 0.00 0.00 27.90M
Cash Used for Financing Activities
Issuance of Capital Stock 1.16M 260.84M 70.29M 130.44M
Repayment of Long-Term Debt 0.00 0.00 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -9.19M 0.00 0.00 0.00
Net Cash From Financing Activities 279.48M 260.84M 70.29M 158.35M
Effect of Exchange Rate Changes -690.00K 35.00K 12.00K 42.00K
Net Change in Cash & Cash Equivalents 159.45M 179.13M 5.86M 127.73M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

CLVS Clovis Oncology Inc

Chart of CLVS

Analysts Ratings for CLVS

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 2 3
Moderate Buy 0 0 0 0
Hold 2 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

CLVS Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs